Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment Through Hypothesis-Driven Systems Medicine Using CoVex.
Assay Drug Dev Technol
; 18(8): 348-355, 2020.
Article
in English
| MEDLINE | ID: covidwho-915847
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has developed into a pandemic causing major disruptions and hundreds of thousands of deaths in wide parts of the world. As of July 3, 2020, neither vaccines nor approved drugs for effective treatment are available. In this article, we showcase how to individuate drug targets and potentially repurposable drugs in silico using CoVex a recently presented systems medicine platform for COVID-19 drug repurposing. Starting from initial hypotheses, CoVex leverages network algorithms to individuate host proteins involved in COVID-19 disease mechanisms, as well as existing drugs targeting these potential drug targets. Our analysis reveals GLA, PLAT, and GGCX as potential drug targets, and urokinase, argatroban, dabigatran etexilate, betrixaban, ximelagatran and anisindione as potentially repurposable drugs.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug Repositioning
/
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Assay Drug Dev Technol
Journal subject:
Pharmacology
Year:
2020
Document Type:
Article
Affiliation country:
Adt.2020.1010
Similar
MEDLINE
...
LILACS
LIS